Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2022-05-04 Call Transcript
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Schedule of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 90% confidence The document is a notification about an upcoming Earnings Conference Call scheduled for May 19, 2022. It provides details on how to join the call, including dial-in numbers and replay information. It explicitly states that the transcript of the Earnings Call will be available on the company's website after the call. The document does not contain any financial results or substantive financial data itself, but rather serves as an announcement for the event where such information will be discussed. According to the classification rules, a document announcing an earnings call or conference call is classified as a Call Transcript (CT) if it contains the full transcript, but this document only announces the call and provides logistics, not the transcript itself. However, since the document is about the Earnings Conference Call and is the announcement of the call, the best fitting category is Call Transcript (CT) as it relates directly to the earnings call event. Confidence is high because the document clearly centers on the earnings call event and its details.
2022-05-04 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Bortezomib for Injection) in the US market by Gland Pharma Limited. It references regulatory approval (ANDA approval from US FDA) and provides background information about the company and the product market. The document is short (3690 characters) and serves as an announcement rather than a detailed financial or regulatory report. It does not contain financial statements, management discussion, voting results, or any detailed regulatory filing content. It is clearly a press release about a product launch, which fits best under the category of a general regulatory announcement or miscellaneous filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-05-04 English
ESOP/ESPS/SBEB Scheme
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the allotment of equity shares following the exercise of Employee Stock Options (ESOP). It mentions the increase in the company's issued share capital due to this allotment. The content focuses on a capital change event, specifically the issuance of new shares, and references compliance with SEBI regulations. The document length is short (1312 characters) and it is an announcement rather than a detailed report or financial statement. Therefore, it fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other filing types.
2022-04-29 English
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is titled 'Report of the Monitoring Agency for the Quarter ending March 31, 2022' and is issued pursuant to SEBI regulations related to the utilization of IPO proceeds. It contains detailed financial data on the use of funds raised through an Initial Public Offering, including itemized costs, progress on objectives, and deployment of unutilized proceeds. The document is a monitoring report by an external agency (Axis Bank Limited) on the use of IPO proceeds for a specific quarter. It is not an annual or interim financial report, nor is it an earnings release or a regulatory filing. It is a specialized report related to capital raised and its utilization, which fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains substantive financial data, not merely an announcement or certification, so it is not RPA or RNS.
2022-04-29 English
Postal Ballot
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal communication from Gland Pharma Limited to stock exchanges (BSE and NSE) dated April 21, 2022. It reports the results of voting through Postal Ballot (remote e-voting) pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content includes details about resolutions passed by shareholders, specifically the re-appointment of a Managing Director & CEO and appointment of a Director. It also mentions the inclusion of the Scrutinizer's Report as an annexure. The document is focused on announcing the official voting results of shareholder resolutions, not the full AGM materials or the resolutions themselves. It is not an annual report, earnings release, or management discussion. The key regulatory reference and the nature of the content align with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support this classification with high confidence.
2022-04-21 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a tabular disclosure under Regulation 31(4), listing promoters and promoter groups of Gland Pharma Limited for the financial year ending 31-Mar-2022. This type of disclosure corresponds to notifications about major shareholdings or promoter holdings. It is not a full report, audit, or financial statement, nor is it an announcement of voting results or management changes. The content fits the definition of a Major Shareholding Notification, which involves reporting changes or status of significant share ownership levels.
2022-04-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.